Credit score: Unsplash/CC0 Public Area
The anti-obesity medicine tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight problems, decreased obesity-associated breast most cancers progress in a mouse mannequin, in response to a research being offered Saturday at ENDO 2025, the Endocrine Society’s annual assembly in San Francisco, Calif.
“Obesity is a significant risk factor for breast cancer, and while it is very preliminary data, our studies in mice suggest that these new anti-obesity drugs may be a way to reduce obesity-associated breast cancer risk or improve outcomes,” mentioned research writer Amanda Kucinskas, B.S., a Ph.D. candidate within the labs of Drs. Erin Giles and Kanakadurga Singer on the College of Michigan in Ann Arbor, Mich.
Current analysis has proven that having weight problems can result in worse breast most cancers outcomes in comparison with those that should not have weight problems, and weight reduction can enhance outcomes. Nonetheless, there are a lot of challenges with conventional weight reduction strategies.
Kucinskas and colleagues leveraged tirzepatide, one among a brand new class of efficient anti-obesity drugs that concentrate on GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. The researchers sought to be taught whether or not or not tirzepatide would scale back obesity-associated breast most cancers progress.
This mouse research included 16 mice. The 9-week-old C57BL/6 mice had been fed a 40% high-fat eating regimen and housed in a heat setting to induce weight problems. At 32 weeks of age, the mice with weight problems had been randomly assigned injections of tirzepatide or a placebo each different day for 16 weeks. Tumor volumes had been measured twice weekly.
The researchers discovered that the anti-obesity drug decreased physique weight and physique fats by roughly 20% in mice, just like the quantity of weight reduction achieved by ladies on this drug. They discovered this was primarily as a consequence of a lack of adipose mass, with a discount in adipose depot weights in comparison with controls.
The anti-obesity drug additionally decreased tumor quantity in comparison with the controls. On the finish of the research, the researchers discovered that tumor quantity was considerably correlated with physique weight, complete adipose mass and the quantity of fats saved within the liver.
“While these are very preliminary results, they suggest that this new anti-obesity drug may also have a beneficial impact on breast cancer outcomes,” Kucinskas mentioned.
Ongoing research are underway in collaboration with Dr. Steve Hursting’s lab on the College of North Carolina at Chapel Hill to separate the load loss from the tumor-specific results of tirzepatide.
Supplied by
The Endocrine Society
Quotation:
Mouse research finds tirzepatide slowed obesity-associated breast most cancers progress (2025, July 12)
retrieved 12 July 2025
from https://medicalxpress.com/information/2025-07-mouse-tirzepatide-obesity-breast-cancer.html
This doc is topic to copyright. Aside from any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.
